| Customization: | Available |
|---|---|
| Powder: | Yes |
| Customized: | Customized |
|
Still deciding? Get samples of US$ 1/kg
Request Sample
|
Suppliers with verified business licenses
Audited Supplier Audited by an independent third-party inspection agency
Nootropic Supplyment CAS 69353-21-5 1953-04-4 Galantamine Hbr / Galantamine Hydrobromide
| Product name: Galantamine Hydrobromide |
| Other Name:galanthamine HBr |
| Appearance:White powder |
| CAS:1953-04-4 |
| M.F.:C17H22BrNO3 |
| M.W.:368.27 |
| Specification:99% |
Galanthamine Hydrobromide is the anti-cholinesterase, weak effect. It has strong effect to the central nervous system through the blood brain barrier. It mainly cures the infantile paralysis sequelae, sweeny and myasthenia gravis pseudoparalytica, etc. It also can be applied to puerilism, posttraumatic apoplexy, polyneuritis and radiculitis.Clinic function: mainly used in myasthenia gravis, poliovirus quiescent stage and sequela, also in polyneuritis, funiculitis and sensorimotor barrier caused by nervous system disease or traumatism. It's major used in Alzheimer's disease, has the principal function for dement and dysmnesia caused by organic brain damage.
| ITEM | SPECIFICATION | RESULT | METHOD |
| Appearance | White powder, neutral odor, highly hygroscopic | Conforms | Visual |
| Identification | Standard solution and test solution same spot,RF | Conforms | TLC |
| Specific Optical | -2.4°~ -2.8° | -2.72° | |
| Heavy metals (as PB) | ≤10ppm | Conforms | AAS |
| Sulfate (SO4) | ≤0.02% | Conforms | Colorimetry |
| Chloride (Cl) | ≤0.02% | Conforms | Colorimetry |
| Phosphate Ion (P) | ≤5ppm | Conforms | Colorimetry |
| Residual solvent(ethanol) | ≤1.0% | Conforms | HS-GC |
| pH | 4.5~7.0 | 5.10 | |
| Related substance | Spot not bigger than standard solution spot | No spot | TLC |
| Water Content | ≤2% | 0.26% | KF |
| Assay (dried basis) | 98.0%--102.0% | 99.48% | Potentiometric titration |
| Assay (dried basis) | 98.5%--100% | 99.2% | HPLC |
Function:
Galantamine Hydrobromide is used for benign memory disorders to improve the patient's ability to point memory, associative learning, image recall, meaningless graphic recognition and portrait recall. It also improves memory impairment caused by dementia patients and brain organic diseases.
){kind=link}